| Literature DB >> 34996800 |
Linfeng He1, Lijuan Bai1, Lihua Liu1, Yun Liu1, Ruiyun Wang1, Yaoling Wang1, Man Liao1, Yizhou Wan2, Benling Qi3.
Abstract
OBJECTIVE: To evaluate arteriosclerosis using Cardio-Ankle Vascular Index (CAVI) and to explore the relation between the body fat percentage (BFP) and CAVI.Entities:
Keywords: Cardio-Ankle Vascular Index; arteriosclerosis; body fat percentage
Mesh:
Year: 2022 PMID: 34996800 PMCID: PMC8744127 DOI: 10.1136/bmjopen-2021-056281
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Baseline characteristics
| BFP | Q1 | Q2 | Q3 | Q4 | P value |
| N | 277 | 296 | 289 | 290 | |
| Age (years, mean±SD) | 54.80±14.47 | 56.46±13.60 | 58.46±13.86 | 61.66±13.65 | <0.001 |
| BMI (kg/m2, mean±SD) | 22.12±2.59 | 24.38±2.61 | 25.16±3.12 | 26.05±3.70 | <0.001 |
| BFP (%, mean±SD) | 18.83±3.80 | 24.01±0.97 | 27.26±1.10 | 33.27±3.16 | <0.001 |
| SBP (mm Hg, mean±SD) | 125.09±15.75 | 128.98±16.54 | 130.16±17.48 | 134.37±18.98 | <0.001 |
| DBP (mm Hg, mean±SD) | 81.13±10.33 | 83.54±10.80 | 82.45±10.20 | 81.73±10.84 | 0.040 |
| CAVI (m/s, mean±SD) | 8.06±1.35 | 8.17±1.36 | 8.21±1.58 | 8.27±1.47 | 0.359 |
| TC (mmol/L, mean±SD) | 4.32±1.08 | 4.39±1.05 | 4.47±1.12 | 4.45±1.14 | 0.355 |
| TG (mmol/L, median (Q1–Q3)) | 1.15 (0.83–1.75) | 4.45 (3.75–5.04) | 4.37 (3.61–5.23) | 1.40 (1.03–2.00) | <0.001 |
| HDL-C (mmol/L, mean±SD) | 1.25±0.36 | 1.14±0.33 | 1.17±0.34 | 1.24±0.34 | <0.001 |
| LDL-C (mmol/L, median (Q1–Q3)) | 2.49 (1.97–3.06) | 2.63 (1.98–3.18) | 2.61 (2.03–3.25) | 2.60 (1.92–3.30) | 0.255 |
| Fasting glucose (mmol/L, median (Q1–Q3)) | 4.83 (4.49–5.36) | 4.94 (4.61–5.60) | 5.00 (4.57–5.62) | 5.13 (4.69–5.73) | <0.001 |
| Gender (n, %) | <0.001 | ||||
| Female | 26 (9.39%) | 42 (14.19%) | 78 (26.99%) | 208 (71.72%) | |
| Male | 251 (90.61%) | 254 (85.81%) | 211 (73.01%) | 82 (28.28%) | |
| CHD (n, %) | 0.842 | ||||
| No | 226 (82.78%) | 230 (80.42%) | 229 (80.07%) | 231 (80.49%) | |
| Yes | 47 (17.22%) | 56 (19.58%) | 57 (19.93%) | 56 (19.51%) | |
| Hypertension (n, %) | <0.001 | ||||
| No | 154 (56.41%) | 110 (38.46%) | 116 (40.42%) | 112 (38.89%) | |
| Yes | 119 (43.59%) | 176 (61.54%) | 171 (59.58%) | 176 (61.11%) | |
| Diabetes (n, %) | 0.001 | ||||
| No | 196 (71.79%) | 175 (60.55%) | 191 (66.55%) | 164 (56.94%) | |
| Yes | 77 (28.21%) | 114 (39.45%) | 96 (33.45%) | 124 (43.06%) | |
| PAD (n, %) | 0.303 | ||||
| No | 72 (26.37%) | 71 (24.83%) | 69 (24.13%) | 57 (19.86%) | |
| Yes | 201 (73.63%) | 215 (75.17%) | 217 (75.87%) | 230 (80.14%) | |
| CKD (n, %) | 0.486 | ||||
| No | 260 (95.24%) | 267 (93.36%) | 272 (95.10%) | 267 (92.71%) | |
| Yes | 13 (4.76%) | 19 (6.64%) | 14 (4.90%) | 21 (7.29%) | |
| COPD (n, %) | 0.420 | ||||
| No | 265 (97.07%) | 277 (96.85%) | 277 (96.85%) | 273 (94.79%) | |
| Yes | 8 (2.93%) | 9 (3.15%) | 9 (3.15%) | 15 (5.21%) | |
| Osteoporosis (n, %) | 0.042 | ||||
| No | 231 (84.62%) | 250 (87.41%) | 245 (85.66%) | 228 (79.17%) | |
| Yes | 42 (15.38%) | 36 (12.59%) | 41 (14.34%) | 60 (20.83%) | |
| Fatty liver (n, %) | <0.001 | ||||
| No | 196 (71.27%) | 164 (56.36%) | 154 (53.66%) | 139 (48.26%) | |
| Yes | 79 (28.73%) | 127 (43.64%) | 133 (46.34%) | 149 (51.74%) | |
| Smoking (n, %) | <0.001 | ||||
| No | 163 (59.27%) | 172 (59.11%) | 200 (69.69%) | 251 (87.15%) | |
| Yes | 112 (40.73%) | 119 (40.89%) | 87 (30.31%) | 37 (12.85%) | |
| Drinking (n, %) | <0.001 | ||||
| No | 190 (69.09%) | 175 (60.14%) | 204 (71.08%) | 255 (88.54%) | |
| Yes | 85 (30.91%) | 116 (39.86%) | 83 (28.92%) | 33 (11.46%) | |
| Diuretic use (n, %) | 0.388 | ||||
| No | 261 (94.22%) | 271 (91.55%) | 265 (91.70%) | 262 (90.34%) | |
| Yes | 16 (5.78%) | 25 (8.45%) | 24 (8.30%) | 28 (9.66%) |
BFP, body fat percentage; BMI, body mass index; CAVI, Cardio-Ankle Vascular Index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
Figure 1Scatterplot of age, BMI and BFP. (A) Age. (B) BMI. BFP, body fat percentage; BMI, body mass index.
Univariate linear regression analysis
| Statistics | β (95% CI) | P value | |
| Age | 57.87±14.11 | 0.06 (0.06 to 0.07) | <0.001 |
| Gender | |||
| Female | 354 (30.73%) | Reference | |
| Male | 798 (69.27%) | 0.32 (0.14 to 0.50) | <0.001 |
| BMI | 24.46±3.36 | −0.06 (−0.09 to –0.04) | <0.001 |
| BFP | 25.91±5.80 | 0.00 (−0.01 to 0.02) | 0.612 |
| SBP | 129.70±17.53 | 0.02 (0.02 to 0.03) | <0.001 |
| DBP | 82.23±10.57 | 0.01 (−0.00 to 0.02) | 0.075 |
| TC | 4.41±1.10 | −0.23 (−0.31 to –0.16) | <0.001 |
| TG | 1.84±1.76 | −0.07 (−0.12 to –0.02) | 0.005 |
| LDL-C | 2.82±6.30 | −0.01 (−0.02 to 0.01) | 0.443 |
| HDL-C | 1.20±0.35 | −0.22 (−0.47 to 0.02) | 0.078 |
| Fasting glucose | 5.46±2.19 | 0.05 (0.01 to 0.09) | 0.011 |
| Hypertension | |||
| No | 492 (43.39%) | Reference | |
| Yes | 642 (56.61%) | 0.70 (0.54 to 0.87) | <0.001 |
| Diabetes | |||
| No | 726 (63.85%) | Reference | |
| Yes | 411 (36.15%) | 0.66 (0.48 to 0.83) | <0.001 |
| PAD | |||
| No | 269 (23.76%) | Reference | |
| Yes | 863 (76.24%) | 0.84 (0.64 to 1.03) | <0.001 |
| CHD | |||
| No | 916 (80.92%) | Reference | |
| Yes | 216 (19.08%) | 1.05 (0.84 to 1.25) | <0.001 |
| Osteoporosis | |||
| No | 954 (84.20%) | Reference | |
| Yes | 179 (15.80%) | 0.56 (0.34 to 0.79) | <0.001 |
| CKD | |||
| No | 1066 (94.09%) | Reference | |
| Yes | 67 (5.91%) | 1.09 (0.74 to 1.44) | <0.001 |
| COPD | |||
| No | 1092 (96.38%) | Reference | |
| Yes | 41 (3.62%) | 1.18 (0.74 to 1.63) | <0.001 |
| Fatty liver | |||
| No | 653 (57.23%) | Reference | |
| Yes | 488 (42.77%) | −0.15 (−0.32 to 0.02) | <0.001 |
| Smoking | |||
| No | 786 (68.89%) | Reference | |
| Yes | 355 (31.11%) | 0.09 (−0.09 to 0.27) | 0.347 |
| Drinking | |||
| No | 824 (72.22%) | Reference | |
| Yes | 317 (27.78%) | −0.17 (−0.36 to 0.01) | 0.068 |
BFP, body fat percentage; BMI, body mass index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
Different linear regression models analysis between BFP and CAVI
| Exposure | Non-adjusted | Adjust I | Adjust II |
| BFP | 0.00 (−0.01 to 0.02, 0.612) | 0.03 (0.01 to 0.05, 0.011) | 0.03 (0.00 to 0.05, 0.022) |
| BFP (quartile) | |||
| Q1 | Reference | Reference | Reference |
| Q2 | 0.11 (−0.13 to 0.35, 0.344) | 0.23 (0.03 to 0.42, 0.024) | 0.20 (0.00 to 0.40, 0.049) |
| Q3 | 0.15 (−0.09 to 0.39, 0.216) | 0.29 (0.07 to 0.51, 0.010) | 0.29 (0.06 to 0.51, 0.012) |
| Q4 | 0.21 (−0.03 to 0.45, 0.081) | 0.52 (0.22 to 0.82, <0.001) | 0.49 (0.18 to 0.80, 0.002) |
| P for trend | 0.07 (−0.01 to 0.14, 0.081) | 0.15 (0.06 to 0.25, 0.002) | 0.15 (0.05 to 0.25, 0.002) |
Non-adjusted model adjusts for: none.
Adjust I model adjusts for: age; gender and BMI.
Adjust II model adjusts for: age, gender, BMI, SBP, hypertension, diabetes, PAD, CHD, osteoporosis, CKD, COPD, fatty liver, smoking, drinking, DBP, TC, HDL-C, TG, fasting glucose, LDL-C and diuretic use.
BFP, body fat percentage; BMI, body mass index; CAVI, Cardio-Ankle Vascular Index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
Figure 2Fitting curve between BFP and CAVI. A non-linear relationship between BFP and CAVI after adjusting for age, gender, BMI, SBP, hypertension, diabetes, PAD, CHD, osteoporosis, CKD, COPD, fatty liver, smoking, drinking, DBP, TC, HDL-C, TG, fasting glucose, LDL-C and diuretic use. BFP, body fat percentage; BMI, body mass index; CAVI, Cardio-Ankle Vascular Index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
Threshold analysis between BFP and CAVI
| Inflection point of BFP | Effect size (β) | 95% CI | P -value |
| <20.6 | −0.02 | −0.06 to 0.03 | 0.424 |
| ≥20.6 | 0.05 | 0.02 to 0.07 | 0.001 |
Adjusted: age, gender, BMI, SBP, hypertension, diabetes, PAD, CHD, osteoporosis, CKD, COPD, fatty liver, smoking, drinking, DBP, TC, HDL-C, TG, fasting glucose, LDL-C and diuretic use.
BFP, body fat percentage; BMI, body mass index; CAVI, Cardio-Ankle Vascular Index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
Association between BFP and CAVI in subgroups
| Characteristic | No. of participants | Effect size (95% CI) | P interaction |
| Age (years) | 0.038 | ||
| 18–48 | 287 | 0.05 (0.01 to 0.09) | |
| 49–54 | 245 | 0.05 (0.01 to 0.09) | |
| 55–65 | 319 | 0.05 (0.02 to 0.08) | |
| 66–95 | 301 | 0.03 (0.01 to 0.06) | |
| Gender | 0.873 | ||
| Female | 346 | 0.03 (–0.00 to 0.06) | |
| Male | 766 | 0.03 (0.00 to 0.06) | |
| Hypertension | 0.348 | ||
| No | 479 | 0.02 (–0.00 to 0.05) | |
| Yes | 633 | 0.03 (0.01 to 0.06) | |
| Diabetes | 0.879 | ||
| No | 707 | 0.03 (0.00 to 0.05) | |
| Yes | 405 | 0.03 (–0.00 to 0.06) | |
| PAD | 0.964 | ||
| No | 262 | 0.03 (–0.00 to 0.06) | |
| Yes | 850 | 0.03 (0.00 to 0.05) | |
| CHD | 0.900 | ||
| No | 902 | 0.03 (0.00 to 0.05) | |
| Yes | 210 | 0.03 (–0.01 to 0.06) | |
| Osteoporosis | 0.065 | ||
| No | 939 | 0.03 (0.01 to 0.06) | |
| Yes | 173 | 0.01 (–0.02 to 0.04) | |
| CKD | 0.255 | ||
| No | 1047 | 0.03 (0.01 to 0.06) | |
| Yes | 65 | 0.01 (–0.04 to 0.05) | |
| COPD | 0.908 | ||
| No | 1073 | 0.03 (0.00 to 0.05) | |
| Yes | 39 | 0.03 (–0.04 to 0.09) | |
| Fatty liver | 0.121 | ||
| No | 633 | 0.02 (–0.00 to 0.05) | |
| Yes | 479 | 0.04 (0.01 to 0.07) | |
| Smoking | 0.240 | ||
| No | 763 | 0.03 (0.01 to 0.06) | |
| Yes | 349 | 0.02 (–0.02 to 0.05) | |
| Drinking | 0.166 | ||
| No | 804 | 0.03 (0.01 to 0.06) | |
| Yes | 308 | 0.01 (–0.03 to 0.05) | |
| BMI | 0.173 | ||
| <18.5 | 32 | −0.07 (–0.14 to 0.00) | |
| ≥18.5, <25 | 602 | −0.00 (–0.03 to 0.02) | |
| ≥25 | 478 | −0.00 (–0.03 to 0.02) | |
| Fasting glucose (tertile) | 0.437 | ||
| Low | 371 | 0.02 (–0.00 to 0.05) | |
| Middle | 364 | 0.04 (0.01 to 0.07) | |
| High | 377 | 0.03 (–0.00 to 0.06) | |
Above subgroups were adjusted for age, gender, BMI, SBP, hypertension, diabetes, PAD, CHD, osteoporosis, CKD, COPD, fatty liver, smoking, drinking, DBP, TC, HDL-C, TG, fasting glucose, LDL-C and diuretic use, except for its stratified variables.
BMI, body mass index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.